Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fortrea (Nasdaq: FTRE), a global contract research organization, has announced the granting of inducement awards to a new employee. The award consists of 75,000 restricted stock units (RSUs) that will vest over three years in equal annual installments, beginning September 12, 2026.

The RSUs are granted under the Company's Amended and Restated 2025 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an employment inducement for the new hire.

News Market Reaction

+0.99%

1 alert

+0.99% News Effect

+$9M Valuation Impact

$917M Market Cap

0.8x Rel. Volume

On the day this news was published, FTRE gained 0.99%, reflecting a mild positive market reaction. This price movement added approximately $9M to the company's valuation, bringing the market cap to $917M at that time.

Data tracked by StockTitan Argus on the day of publication.

DURHAM, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on September 12, 2025, to one newly hired employee. The award consisted of 75,000 RSUs that vest in three equal annual installments starting September 12, 2026, subject to the employee’s continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company’s Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to the individual becoming a new employee of the Company.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, tracy.krumme@fortrea.com

Sue Zaranek (Media) – 919-943-5422, media@fortrea.com

Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

FAQ

What type of inducement award did Fortrea (FTRE) grant to its new employee?

Fortrea granted 75,000 restricted stock units (RSUs) to one newly hired employee on September 12, 2025.

What is the vesting schedule for Fortrea's (FTRE) new RSU grant?

The RSUs will vest in three equal annual installments, with the first vesting date starting September 12, 2026, subject to continued employment.

Under which plan were Fortrea's (FTRE) inducement awards granted?

The RSUs were granted under Fortrea's Amended and Restated 2025 Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

What is the purpose of Fortrea's (FTRE) RSU inducement award?

The RSU award serves as an inducement material to attract the new employee to join Fortrea, granted in accordance with Nasdaq listing rules.